SCHEMBL16375215

SCHEMBL16375215

O=C(NC(Cc1ccc(-c2ncc(-c3ccccc3)cn2)cc1)C(=O)N1CC(C(=O)O)C1)c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ PYGL P06737 1/20 0.48
▸ KMT2A Q03164 1/20 0.47
▸ ACE2 Q9BYF1 1/20 0.44
▸ HCRTR2 O43614 2/20 0.42
▸ ACE P12821 1/20 0.42
▸ CTSS P25774 3/20 0.42
▸ CTSB P07858 2/20 0.42
▸ CTSK P43235 2/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ S1PR4 O95977 1/20 0.41
▸ S1PR1 P21453 1/20 0.41
▸ S1PR5 Q9H228 1/20 0.41
▸ KDM1A O60341 1/20 0.41
▸ CTSL P07711 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16375209 0.92 KMT2A (0.47) KMT2AACE2ACE
SCHEMBL17994249 0.92 PYGL (0.47) PYGLKMT2AACE2HCRTR2ACE
SCHEMBL16375211 0.91 KMT2A (0.46) KMT2AACE2ACE
SCHEMBL16375214 0.89 HSPA5 (0.46) PYGLS1PR4S1PR1S1PR5CTSL
SCHEMBL17994247 0.85 CCR1 (0.46) KMT2AACE2HCRTR2ACE
SCHEMBL17834564 0.84 PYGL (0.41) PYGLKMT2AACE2ACES1PR4
SCHEMBL17834627 0.84 CCR1 (0.42) PYGLL3MBTL1S1PR4S1PR1S1PR5
SCHEMBL17834871 0.83 S1PR1 (0.43) S1PR4S1PR1S1PR5
SCHEMBL17994252 0.83 FPR2 (0.47) KMT2AACE2ACE
SCHEMBL17834825 0.83 S1PR1 (0.42) S1PR1S1PR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170313717-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2017-11-02 — — US disclosed
US-9598430-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2017-03-21 — — US disclosed
US-20160214993-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2016-07-28 — — US disclosed
US-20150011527-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2015-01-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170313717-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R PYGL 779/4885KMT2A 4232/4885ACE2 3162/4885
US-20160214993-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R PYGL 779/4885KMT2A 4232/4885ACE2 3162/4885
US-20150011527-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R PYGL 779/4885KMT2A 4232/4885ACE2 3162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback